Background. Higher daptomycin doses are advocated for select methicillin-resistant Staphylococcus aureus (MRSA)-related infections, but the probabilities of target attainment (PTA) and toxicity of these doses have not been characterized in critically ill patients.
Guidelines by the Infectious Diseases Society of America for the treatment of methicillin-resistant Staphylococcus aureus (MRSA) recommend consideration of high-dose (10 mg/kg) daptomycin in patients with persistent MRSA bacteremia associated with vancomycin failure [1] . Experts suggest that use of 8-10 mg/kg intravenously dosed once daily should be considered in patients with infective endocarditis [1] . These recommendations are grounded on the concentration-dependent pharmacokinetic (PK)-pharmacodynamic (PD) profile of daptomycin [2] . Suboptimal daptomycin area under the concentration-time curve (AUC) values indexed to the minimum inhibitory concentration (MIC), or AUC/MIC, have been linked to clinical failure, whereas trough (C min ) concentrations are correlated with skeletal muscle toxicity [2, 3] .
Recent studies demonstrate marked variability in the PK of daptomycin in acutely ill patients despite use of current recommended doses [4, 5] . The original population PK model that serves as the basis of currently approved daptomycin doses identified daptomycin clearance (CL) to increase (and thus exposure to decrease) with estimated creatinine clearance (eCLcr), body temperature, and male sex [6] . Despite these findings, the daptomycin dose is currently only increased for weight, decreased for eCLcr <30 mL/minute, and not adjusted for any surrogate markers of critical illness [7, 8] . The current study was performed to characterize the PK and outcomes of daptomycin use in critically ill patients to identify subgroups of patients that may have augmented daptomycin CL and resultant low drug exposures despite use of 6-8 mg/kg/day doses. The secondary objective of this study was to estimate the probability of target attainment (PTA) and toxicity of alternate daptomycin dosing regimens.
MATERIALS AND METHODS

Study Design
This open-label, prospective study was carried out in the Policlinico Umberto I of Rome, Italy, during November 2009 through November 2011. Daptomycin therapy including the initial dosing regimen was selected based on the personal judgment of the attending physician or the infectious diseases consultant. Patient demographics, clinical and laboratory findings, microbiological data, duration of daptomycin therapy, and outcome information were collected. The study was approved by the respective institutional review board, and written informed consent was obtained from all patients prior to participation.
Selection Criteria
Patients were eligible for study participation if they were aged ≥18 years and had an initial positive bacterial blood culture or other sterile site for a gram-positive pathogen. Patients were excluded from participation if any of the following criteria were met: (1) known hypersensitivity to daptomycin or product excipients; (2) suspected cases of meningitis or osteomyelitis; (3) documented or suspected pneumonia caused by a grampositive organism; (4) infection with a daptomycin-resistant organism; (5) treatment with daptomycin or other gram-positive bacteria-active antimicrobial in the 7 days preceding study initiation; (6) pregnant or lactating; (7) receipt of any renal replacement therapies such as hemodialysis or peritoneal dialysis; (8) presence or history of rhabdomyolysis; (9) signs or symptoms of myopathy with an elevation of creatine phosphokinase concentrations. All episodes of healthcare-associated infection were defined according to the standard definitions of the Centers for Disease Control and Prevention [9] . Bloodstream infections, including sepsis, severe sepsis, and septic shock, were defined according to standard international criteria [10] . Bacteremia was defined as the isolation of microorganism in ≥2 separate blood cultures with clinical evidence of infection, and infective endocarditis was diagnosed according to the modified Duke criteria [11, 12] .
Daptomycin Dosing and Plasma Concentration Measurement
Daptomycin (Novartis Pharma) was infused intravenously over 30 minutes every 24 hours based on a clinician-chosen dosage of 6 or 8 mg/kg/day. A maximum of 14 blood samples (5 mL) were collected in heparinized tubes over a 5-dose administration sequence (96 hours). Sampling was done prior to the administration of the first dose, at 30 minutes (end of infusion), and at 1, 2, 4, 8, 12, and 24 hours after the initial dose. Additional blood samples were collected at the end of infusion ( peak) and prior to the subsequent dose (trough) for doses 2-5. Daptomycin plasma concentrations were assayed as previously reported by a validated high-performance liquid chromatography ultraviolet detection technique [5] .
Population Pharmacokinetic Analysis
Population pharmacokinetic (POP-PK) systems analysis was performed using ADAPT 5 with the maximum likelihood expectation maximization algorithm and model discrimination based on Akaike information criterion (AIC) [13, 14] . Modeling and identification of potential subpopulations was performed in a blinded fashion. All clinical outcomes data were collected a priori, and the blinded investigator (M.P.P.) was only provided concentration-time, demographic and anthropometric measures, and laboratory parameter data. Several potential covariates of daptomycin PK system parameters were evaluated post hoc. Additional methodological details are included in the Supplementary Data.
Model Validation and Dosing Simulations
To ensure that the final POP-PK model adequately described the observed data, a visual predictive check was performed. After final model validation, individual patient parameter estimates and actual doses administered were used to compute individualized maximum concentrations (C max ), C min , area under the curve integrated from time 0 to 24 hours (AUC 0-24 ), and time 0 to infinity (AUC 0-inf ) values. In addition, various dosing regimens were simulated (n = 5000) to ascertain PTA and toxicity. The mean AUC 0-24 /MIC associated with a static, 1-log killing, and 2-log killing effect against S. aureus is 438 (SD, 67), 666 (SD, 87), and 1061 (SD, 296), respectively [15] . A daptomycin AUC 0-24 /MIC ratio of <666 has also been associated with worse clinical outcomes, including death, but remains to be validated by other groups [5] . In the absence of a wellestablished target, we evaluated the PTA of an AUC 0-24 /MIC ratio of ≥666 ± 1 SD (≥579, ≥666, ≥753) for weight-based doses (6-10 mg/kg) and fixed doses (500-1000 mg) by Monte Carlo simulation (MCS) (n = 5000) as suggested by the European Committee on Antimicrobial Susceptibility Testing (EUCAST) rationale document [16] . The PTA for achievement of the 3 aforementioned targets were determined for a log 2 MIC range of 0.016-2 mg/L using the EUCAST wild-type MIC distribution for S. aureus (n = 35 976) [16] . The cumulative fraction of response (CFR) was calculated as previously described [17] . The probability of achieving C min ≥ 24.3 mg/L (associated with skeletal muscle toxicity) with the aforementioned doses was computed [3, 18] .
Statistical Analysis
All statistical analyses were performed using Stata software, version 11 (StataCorp, College Station, Texas). Based on the observed distribution, patients within the upper quartile (75th percentile) of daptomycin CL were compared to the rest of the population. Categorical variables were compared using Fisher exact test and the Mann-Whitney test for continuous variables. Statistical significance was based on a 2-sided P value of ≤.05. Logistic regression was used to assess the relationship between PK-PD indices and mortality.
RESULTS
Population Baseline Characteristics
Sixty-nine patients were screened and 58 patients were enrolled after exclusion ( Figure 1 ). Blood samples could not be collected in 7 patients, and 1 patient was withdrawn due to creatine phosphokinase elevation after receipt of 2 doses of daptomycin 8 mg/kg. Thus, 50 patients were included; the demographic characteristics of the population are outlined in Table 1 . The patients were primarily of white race (n = 48) and included similar proportions of males and females. The median (5th, 95th percentile) age, body weight, body mass index, and eCLcr were 70 (42, 86) years, 70 (55, 100) kg, 26 (21, 35) kg/m 2 , and 50.8 (17.1, 139) mL/minute, respectively. The most common type of infections were bloodstream infection (42%) and skin and soft tissue infection (40%). Of 21 patients with bloodstream infection, 4 had an infective endocarditis, 4 had bacteremia secondary to pacemaker pocket infection, 9 had central venous catheter-related bacteremia, 2 had bacteremia associated with a skin and soft tissue infection, and 2 had infection with an unknown focus. An isolate was identified in 88% of patients, and approximately two-thirds of isolates were methicillin-resistant Staphylococcus species. Patients were treated with daptomycin 6 mg/kg (n = 32) or 8 mg/kg (n = 18). The median (5th, 95th percentile) absolute daptomycin dose and duration of treatment was 480 (354, 720) mg and 16 (5, 29) days.
Augmented Clearance
A total of 590 plasma samples were analyzed for daptomycin and each patient contributed a median of 12 (minimum 6, maximum 14) samples. A stepwise description of model development, selection, and validation is provided in the Supplementary Data. In brief, a 1-compartment linear model provided a better fit to the data than a 2-compartment model. The population Figure 1 . Diagram illustrating the number of subjects screened, excluded, enrolled, and withdrawn from the study. Data are presented as mean (standard deviation) unless otherwise specified.
Abbreviations: AUC 0-24 , area under the curve integrated from time 0 to 24 hours; AUC 0-inf , area under the curve integrated from time 0 to infinity; BMI, body mass index; C max , maximum concentration; C min , minimum concentration; eCLcr, estimated creatinine clearance. Figure 2 , a distinct subpopulation of patients with augmented CL was observed. This subpopulation was stratified as 13 patients with a CL value ≥1.36 L/ hour (≥75th percentile), and are subsequently referred to as patients with augmented CL. Inclusion of potential covariates of CL and V 1 identified by univariate analyses did not improve the model. As a key example, the relationship of CL to body weight (P = .403) and eCLcr (P = .071) was not significant, and also did not reduce the AIC when introduced into the model. As illustrated in Figure 3 , patients identified to have augmented CL were distinct from the rest of the population over body weight and eCLcr [8] . Table 1 summarizes population characteristics, drug doses, and observed PK parameters and exposures in the subgroup of patients with augmented CL compared to the rest of the population. Patients with augmented CL had significantly (P < .001) lower C max , AUC 0-24 , and AUC 0-inf values compared to the rest of the population despite receipt of comparable absolute and weight-based daptomycin doses. The marked difference in the exposure of daptomycin is illustrated in Figure 4 .
Association With Clinical Outcomes
The clinical characteristics and outcomes of the population based on independent PK-PD assessment (M.F.) are provided in Table 2 . All 13 patients identified to have augmented CL were discovered to have had bacteremia and/or infective endocarditis. A majority (n = 11) of these patients were infected with MRSA. A diagnosis of severe sepsis or septic shock was also noted in 100% of cases with augmented CL compared to 24% of patients in the rest of the population. The clinical characteristics of patients with severe sepsis or septic shock are included in Table 3 , and show that in-hospital mortality was only observed in these patients primarily with methicillin-resistant Staphyloccus species-associated bloodstream infections. The median (5th, 95th percentile) CL was 0.98 (0.601, 2.10) L/hour in patients with sepsis compared to 0.769 (0.528, 1.92) L/hour in patients without sepsis ( Figure 5A ). Furthermore, mean Sequential Organ Failure Assessment (SOFA) scores were significantly higher in patients with augmented CL, and a significant but poor (R 2 = 0.22) relationship was observed between these parameters ( Figure 5B ). The proportion of patients with inhospital mortality was significantly (P < .001) higher in the patients with augmented CL (30.7%) compared to the rest of the population (10.8%). Although significant association between CL and markers of disease progression were identified, inclusion of MRSA, sepsis, or SOFA scores as bivariate and ordinal terms also did not improve the POP-PK model. No relationships (logistic regression) between PK-PD indices and mortality could be identified based on the limited sample size.
Dosing Simulations
We evaluated the PTA and CFR of weight-based and fixed-dose daptomycin in patients with and without sepsis because this population had a high risk of in-hospital mortality and were likely to have augmented daptomycin CL. Tables 4 and 5 include as a footnote the distribution of system parameters used for this simulation in each group, and this is detailed in the Supplementary Data. For isolates with a MIC ≥0.5 mg/L, the PTA is <85% at the lowest AUC 0-24 /MIC target, using daptomycin 6 mg/kg/day (standard dose) in patients without sepsis. Table 4 shows that CFR >90% for all targets occurs with the 8 and 10 mg/kg/day but not the 6 mg/kg/day doses. As expected, the CFR increases with increasing weight-based dose; however, the probability of C min values ≥24.3 mg/L is 11.0% with 10 mg/kg/day doses. In contrast, use of 500 mg/day is associated with a CFR > 90% for all targets, and the probability that C min values are ≥24.3 mg/L is 1.38% in patients without sepsis. In contrast, higher CL and V 1 values in patients with sepsis demonstrates lower PTA and CFR, and lower probabilities for C min values ≥24.3 mg/L ( Table 5 ). The CFR is >90% for all targets with 10 mg/kg/day or doses >750 mg/day. However, use of 750 mg/day is associated with a higher CFR and lower probability (1.26% vs 2.64%) of C min values ≥24.3 mg/L. 
DISCUSSION
The high morbidity and mortality in critically ill patients with sepsis necessitates use of the optimal antimicrobial dose at the onset of therapy [19] . Critically ill patients are in a dynamic physiologic state, and recent studies suggest the potential for augmented drug CL in this population [20] . Use of standard doses in a population with higher drug CL will lead to lower exposures (AUC) because AUC ≈ dose/CL. Lower exposures may contribute to worse clinical outcomes or emergence of resistance [18] . Daptomycin is an antimicrobial agent with a concentration-dependent PK-PD profile that is approved for use at 6 mg/kg/day in adult patients with MRSA bacteremia [7] . Experts suggest that higher daptomycin doses (8-10 mg/kg/ day) should be considered for this indication [1] . The current study gives credence to this expert opinion by demonstrating that daptomycin exposures are lower in critically ill patients with sepsis ( primarily with MRSA-related bacteremia) when treated with standard doses. We demonstrate that a subpopulation of critically ill patients with augmented daptomycin CL exists; however, this subpopulation is not easily identified by demographic, anthropometric, laboratory, or severity of illness markers. In the absence of predictors of augmented CL and therapeutic drug monitoring (TDM) to individualize daptomycin therapy, alternate dosing suggestions are needed. Our quantitative analyses suggest that higher weight-based doses may achieve the target exposure, but that a minimum threshold dose (500 mg or 750 mg) is expected to be necessary. These higher empiric fixed doses at the onset (first 96 hours) of therapy are also associated with a lower probability for exceeding trough concentration associated with skeletal muscle toxicity than use of 10 mg/kg. Details in support of these conclusions, along with insights and limitations of this study, are provided below. We focus our discussion primarily on daptomycin CL given that the probability of daptomycin effect is driven by AUC. The current study included a cohort of critically ill patients with documented gram-positive infections and was designed to evaluate the population PK-PD of daptomycin in a "real world" setting. Previous population PK-PD analyses included a combination of patient populations (n = 129) and healthy volunteers (n = 153) and observed a median (%RSE) CL of 0.807 (2.9) L/ hour that was influenced by eCLcr, sex, and body temperature [6] . This previous POP-PK model also suggested that the median daptomycin CL should be 1.08 L/hour in a patient with a fever (39.2°C) that is comparable to our population estimates [6] . Importantly, neither model identified body weight to be a predictor of daptomycin CL.
The implications of dosing on weight when this parameter is not predictive of CL were evident from our MCS [21] . We simulated a population with a median (5th, 95th percentile) weight of 72.3 (46.7, 112) kg. Dosing this population with daptomycin 6 mg/kg/day yields a median (5th, 95th percentile) dose of 444 (280, 672) mg. If the CL is independent of weight, then the exposure should be significantly lower in the 46.7-kg (280-mg dose) patient compared to the 112-kg (672-mg dose) patient. Thus, use of an empiric fixed dose of 500 mg (nonsepsis) or 750 mg (sepsis) ensures that underweight patients are not underdosed. Alternatively, higher weight-based doses of 10 mg/kg/day led to a median (5th, 95th percentile) simulated dose of 723 (467, 1120) mg. As expected, higher doses in heavier patients will increase the PTA and CFR but will also increase the probability of toxicity. We demonstrate that doses of 1000 mg/day (10 mg/kg in a 100-kg patient) were associated with the highest probability of C min ≥ 24.3 mg/L in simulations of both groups. Bhavnani et al observed a similar risk in their POP-PK analyses among patients with a body weight >111 kg dosed with 6 mg/kg [3] . They suggested that "dosing based on lean body weight for simulated patients weighing ≥111 kg and on total body weight for simulated patients weighing <111 kg produced AUC distributions that were not significantly different." The equation used to estimate lean body weight in their analyses estimates values <100 kg (for persons <230 kg and <183 cm) and so the maximum dose (6 mg/kg) tested in their analyses would have been <666 mg [22] . Thus, the suggestion that a dose of up to 666 mg achieves comparable exposures in patients >111 kg compared to weight-based dosing in patients ≤111 kg is consistent with our findings. We simply suggest a higher empiric fixed dose of 750 mg because the observed CL among our critically ill patients with sepsis was higher. Although our analyses suggest use of an empiric fixed dose of daptomycin, there are several limitations that should be considered before broad adoption of this idea. Our small sample size may have contributed to our failure to identify specific markers such as eCLcr to be predictive of augmented daptomycin CL. Rapidly changing kidney function, fluid status, and use of vasopressors during sepsis could exert significant variability in daptomycin CL among critically ill patients. Consequently, the data generated in our population may not be generalizable to other critically ill patients, as the time-course and management of this population are highly variable. Although daptomycin TDM could be used to overcome this limitation, our study was not adequately powered or designed to validate the role of TDM. Despite these limitations, our analyses provide a strong rationale for the prospective comparison of a fixed empiric dose (750 mg/day) to weight-based (8-10 mg/kg) dosing of daptomycin in critically ill patients.
In summary, we observed high daptomycin CL among a subset of critically ill patients and significantly lower drug exposures with the use of standard doses. Our simulations suggest that higher doses are likely necessary at the onset of therapy in critically ill patients, and the daptomycin dosing paradigm should be reappraised through prospective studies in this population.
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